# **Special Issue**

# Novel Challenges and Advances in Complex Coronary Interventions

# Message from the Guest Editor

Thanks to the technical progress and the safety improvement in interventional procedures, percutaneous coronary intervention and cardiogenic shock are rapidly expanding toward more complex technical and clinical scenarios. In this clinical setting, the effects of transient coronary occlusion due to the different procedural steps may cause temporary hemodynamic instability. Percutaneous mechanical circulatory support (pMCS) devices emerged as a potential tool to prevent procedure-related hemodynamic compromise by unloading the ventricle and augmenting forward flow, thus potentially reducing ischemia and decreasing myocardial injury ultimately resulting in worse mid and long-term outcomes. The aim of this issue is to evaluate the role of pMCS in high-risk PCI and primary PCI, in particular Impella and ECMO.

#### **Guest Editor**

Dr. Mario Iannaccone

Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, 10100 Turin, Italy

### Deadline for manuscript submissions

closed (30 January 2024)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/129456

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## **Editor-in-Chief**

#### Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

## Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

